Research programme: CTLA-4/FasL fusion protein - KAHR Medical

Drug Profile

Research programme: CTLA-4/FasL fusion protein - KAHR Medical

Alternative Names: KAHR-102

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator KAHR Medical
  • Class Proteins
  • Mechanism of Action Apoptosis stimulants; CD80 antigen inhibitors; CD86 antigen inhibitors; CD95 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 08 Mar 2017 KAHR Medical suspends patient enrolment due to delay in IP production in a phase I/IIa trial for Lymphoma (Second-line therapy or greater) in Israel (SC) (NCT02545361)
  • 15 Dec 2015 KAHR Medical receives regulatory approval in Israel for the initiation of a phase I/II trial before December 2015
  • 15 Sep 2015 Preclinical trials in Cancer in Israel (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top